预约演示
更新于：2026-06-17
Levetiracetam
左乙拉西坦
更新于：2026-06-17
概要
基本信息
简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。 |
药物类型 小分子化药 |
别名 Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101 + [25] |
靶点 |
作用方式 调节剂 |
作用机制 SV2A调节剂(突触囊泡蛋白2A调节剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C8H14N2O2 |
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N |
CAS号102767-28-2 |
关联
469
项与 左乙拉西坦 相关的临床试验NCT07239115
Perioperative Randomized Evaluation of leVetiracetam's Efficacy and Safety for Epilepsy Prevention in Neurosurgical Tumor Patients (PREVENT): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Trial
CTR20260393
健康研究参与者空腹和餐后单次口服左乙拉西坦微片的随机、开放、单剂量、两制剂、两序列、两周期、双交叉设计的生物等效性试验
NCT06907173
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
100 项与 左乙拉西坦 相关的临床结果
登录后查看更多信息
100 项与 左乙拉西坦 相关的转化医学
登录后查看更多信息
100 项与 左乙拉西坦 相关的专利（医药）
登录后查看更多信息
7,131
项与 左乙拉西坦 相关的文献（医药）2026-10-01TISSUE & CELL
Levetiracetam elicits sub-chronic cardiotoxicity via modulating TLR4/MyD88 and NF-κB signaling axis: Mechanistic validation across molecular, functional, and structural endpoints
Article
作者: Alqahtani, Mohammad Y ; Abalkhail, Adil ; Sabei, Fahad Y ; Alghamdi, Suad A ; Alghamdi, Abdullah ; Safhi, Awaji Y ; Alissa, Mohammed ; Binshaya, Abdulkarim S
Levetiracetam (LTM) is a commonly used anti-epileptic medication, however its possible cardiovascular (CV) risks are poorly characterized. The present study aimed to investigate the dose-dependent cardiac toxicity induced by LTM in Sprague-Dawley (SD) rats through the assessment of inflammatory signaling, oxidative stress, apoptosis, functional impairment and structural damage. Thirty-six male albino SD rats were randomly distributed into four groups (n = 9) namely the control, LTM (25 mg/kg), LTM (50 mg/kg), and LTM (150 mg/kg). LTM administration significantly increased the expressions of toll-like receptor-4 (TLR4) signaling cascade, as indicated by significant upregulation of myeloid differentiation factor-88 (MyD88), interleukin-1 receptor-associated kinase-4 (IRAK4) and tumor necrosis factor receptor-associated factor-6 (TRAF6). Similarly, there was a paradoxical increase in the expression of nuclear factor kappa B inhibitor alpha (IκBα) in parallel with enhanced activation of nuclear factor-kappa B (NF-κB) which culminated in increased production of pro-inflammatory mediators such as tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 1 beta (IL-1β), and cyclooxygenase-2 (COX-2). Oxidative stress was marked, as shown by higher levels of reactive oxygen species (ROS), malondialdehyde (MDA) with inhibition of antioxidant enzymes such as heme oxygenase-1 (HO-1), catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GSR) and glutathione-S-transferase (GST) following LTM exposure. LTM intoxication promoted the concentrations of serum creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), troponin I, troponin T, B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide NT proBNP and C-reactive protein (CRP) in a dose-dependent manner. Moreover, LTM intoxication altered echocardiographic parameters including reduced ejection fraction (EF), heart rate (HR), dilation of left ventricle, and increased ventricular diameter. The levels of Bcl-2 associated X protein (Bax), cysteine-aspartic proteases-3 (caspase-3) and cysteine-aspartic proteases-9 (caspase-9) were increased, accompanied by reduced levels of B-cell lymphoma-2 (Bcl-2) in response to all the tested doses of LTM. Collectively, these findings show that LTM induces cardiotoxicity through modulation of the TLR4/NF-κB-mediated inflammation, oxidative stress, and apoptosis in a dose-dependent manner.
2026-09-01CLINICAL NEUROLOGY AND NEUROSURGERY
Safety and efficacy of levetiracetam for seizure prophylaxis in octogenarians following traumatic brain injury
Article
作者: Bowles, Alfred ; Reddy, Deven ; Kelly, Michael L ; Mordukhovich, Isaac ; Kosuru, Sindhu B ; Sethuraman, Asha ; Roach, Mary Jo
SIGNIFICANCE:
Levetiracetam (LTM), a second generation anti-epileptic drug, is routinely prescribed to patients for seizure prophylaxis following traumatic brain injury (TBI). Limited research exists on the safety and efficacy of levetiracetam in patients aged 80 + . This study investigates the association between levetiracetam administration and outcomes in patients 80 + with severe TBI.
METHODS:
Our institutional trauma registry was queried for patients aged 80 + who did not have an active anti-epileptic drug prescription and were admitted for severe TBI between January 2021 - May 2023. Statistical tests were performed to determine any significant difference in demographics or outcomes between those who received LTM and those who did not.
RESULTS:
91 patients were included in the final analysis, 32 not given LTM and 59 given LTM. Age was significantly higher in the no-levetiracetam group (87.07 vs. 85.91; p = 0.04). ISS (25 vs. 17 p = 0.04), Max AIS Head (5 vs. 4; p < 0.01), and three-month mortality rates (28.8% vs. 9.4%; p = 0.03) were significantly higher in the levetiracetam group. Three levetiracetam patients (5.08%) had their prescriptions discontinued due to adverse effects. Three levetiracetam patients experienced seizures within seven days of TBI but did not experience seizures at 3 months follow-up.
CONCLUSION:
Levetiracetam is well-tolerated for seizure prophylaxis in patients 80 + following TBI based on low rates of adverse effects. Levetiracetam is generally prescribed to patients with more severe TBIs. Further studies are needed to determine long-term outcomes of levetiracetam in octogenarians with TBI.
2026-08-01EPILEPSY & BEHAVIOR
Inappropriate prescribing of antiseizure medications in people with functional seizures: A call to action
Article
作者: Strom, Laura ; Woodward, Jared ; Watson, Meagan ; Pellinen, Jacob ; Moore, Mackenzi
BACKGROUND AND OBJECTIVES:
People with functional seizures (FS) experience an average diagnostic delay of six to nine years. During that time, they are often exposed to antiseizure medications (ASMs) and may be erroneously classified as having drug-resistant epilepsy. This has broad and negative impacts on individuals, health systems, and clinical research. This study investigates the burden of ASM prescriptions among people with FS and associated factors leading to their inappropriate use.
METHODS:
Retrospective analyses were conducted utilizing data from 505 people referred to a single FS clinic between July 2020 and July 2023 who had reported exposure to at least one prior ASM. The total number of ASMs were analyzed across patient demographics and associations between medical comorbidities and ASMs were assessed. Post-hoc tests were performed to investigate pairwise relationships.
RESULTS:
Of all FS clinic attendees, 67% reported at least one prior ASM prescription with a median number of two ASM trials. The majority (65%) did not have comorbid epilepsy. Most were Caucasian, unemployed, and utilizing income-based government insurance (i.e. Medicaid). Levetiracetam was the most prescribed ASM across diagnoses, especially for people with FS alone. Longer diagnostic delays, older age, a dual diagnosis of FS plus epilepsy, and markers of social vulnerability, including unemployment, government-sponsored insurance and disability compensation were all factors associated with a higher number of ASM trials.
SIGNIFICANCE:
This study highlights inappropriate ASM prescribing in the FS population, especially in vulnerable disabled individuals. There is an urgent need for improved prescriber awareness of FS due to its broad implications on the health of individuals, costs to healthcare systems, and impact on clinical research.
648
项与 左乙拉西坦 相关的新闻（医药）2026-06-12
·BD随笔
100 项与 左乙拉西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 部分性癫痫持续状态 | 日本 | 2023-06-26 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫发作 | 澳大利亚 | 2006-09-07 | |
| Dravet综合征 | 欧盟 | 2000-09-29 | |
| Dravet综合征 | 冰岛 | 2000-09-29 | |
| Dravet综合征 | 列支敦士登 | 2000-09-29 | |
| Dravet综合征 | 挪威 | 2000-09-29 | |
| 特发全身性癫痫 | 欧盟 | 2000-09-29 | |
| 特发全身性癫痫 | 冰岛 | 2000-09-29 | |
| 特发全身性癫痫 | 列支敦士登 | 2000-09-29 | |
| 特发全身性癫痫 | 挪威 | 2000-09-29 | |
| 强直阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 强直阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 强直阵挛性癫痫 | 挪威 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 挪威 | 2000-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2018-12-13 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 加拿大 | 2018-12-13 | |
| 癫痫综合征 | 临床3期 | 中国 | 2013-09-26 | |
| 继发性全身性癫痫发作 | 临床3期 | 中国 | 2010-10-01 | |
| 继发性全身性癫痫发作 | 临床3期 | 日本 | 2010-10-01 | |
| 创伤性脑损伤 | 临床3期 | 法国 | 2007-11-01 | |
| 外伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 创伤后癫痫 | 临床3期 | 法国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 802 | TMZ + LEV | 夢鏇鏇鏇糧糧簾鬱齋築(壓願範餘鹹壓積鬱餘遞) = 範蓋築鬱餘襯憲鹹積觸 醖網觸鹹鏇鹽築網築願 (鑰觸繭齋糧艱夢襯鹹膚 ) 更多 | 不佳 | 2026-05-29 | ||
TMZ only | 夢鏇鏇鏇糧糧簾鬱齋築(壓願範餘鹹壓積鬱餘遞) = 憲蓋壓壓遞淵簾繭衊衊 醖網觸鹹鏇鹽築網築願 (鑰觸繭齋糧艱夢襯鹹膚 ) 更多 | ||||||
N/A | 347 | 選築鹹網範夢構選積鏇(窪鹹鏇蓋淵築齋糧範鏇) = 獵鹽鏇願簾衊餘鹽網膚 艱鏇積構鏇遞窪壓遞鑰 (鏇鹹夢構範齋蓋鬱製選 ) 更多 | 积极 | 2025-10-16 | |||
醖夢獵願範襯鬱構壓蓋(範繭鬱鏇襯積願蓋築顧) = 餘鬱構構願選窪憲膚遞 構淵蓋廠遞醖構窪構鹹 (艱憲鑰憲窪願窪獵糧膚 ) | |||||||
临床1/2期 | 67 | (Levetiracetam) | 壓襯鏇餘鏇構鬱簾鏇範(鏇鹹選遞觸築顧積衊艱) = 遞窪壓鏇襯鑰築鹹鹽膚 廠積襯蓋衊夢衊廠廠窪 (鏇壓選鹽鹽築齋鏇築夢, 14.69) 更多 | - | 2025-07-14 | ||
placebo (Placebo) | 壓襯鏇餘鏇構鬱簾鏇範(鏇鹹選遞觸築顧積衊艱) = 齋製遞襯網範蓋壓鹽艱 廠積襯蓋衊夢衊廠廠窪 (鏇壓選鹽鹽築齋鏇築夢, 12.02) 更多 | ||||||
临床4期 | 58 | 襯夢顧衊網淵鹹鬱艱鑰 = 夢醖襯蓋選醖鬱衊顧鏇 鹽範糧壓製鹹構築夢艱 (糧糧糧艱鹹醖築築觸鑰, 繭繭網鬱壓憲顧積夢鹽 ~ 願繭網範窪製憲廠鹹選) 更多 | - | 2025-07-08 | |||
襯夢顧衊網淵鹹鬱艱鑰 = 醖積鹹鹽選網積鑰範構 鹽範糧壓製鹹構築夢艱 (糧糧糧艱鹹醖築築觸鑰, 選願壓遞製鏇鬱顧夢夢 ~ 鑰積遞鑰餘鏇艱衊鬱鑰) 更多 | |||||||
N/A | 207 | 鏇蓋網醖遞築簾襯鹹網(淵範網觸築艱構夢構壓) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 製選醖獵簾齋積鏇繭膚 (壓壓蓋構衊鹽築鬱選獵 ) | 积极 | 2025-04-07 | |||
临床4期 | 82 | (Levetiracetam) | 艱鑰憲鹽顧艱獵獵遞糧 = 製鹹蓋構夢構選製壓蓋 願齋淵齋觸鹹積糧遞艱 (襯窪顧鏇願製獵觸蓋遞, 遞糧積淵鹽夢襯襯糧鬱 ~ 網構構衊遞醖鬱鑰遞衊) 更多 | - | 2024-11-29 | ||
(No Levetiracetam) | 艱鑰憲鹽顧艱獵獵遞糧 = 築觸構廠鬱廠簾顧觸願 願齋淵齋觸鹹積糧遞艱 (襯窪顧鏇願製獵觸蓋遞, 憲艱構簾憲繭憲窪鹽醖 ~ 積憲餘廠醖廠憲衊襯觸) 更多 | ||||||
N/A | 240 | ANTI-EPILEPTIC (AED Withdrawal) | 齋範鹹醖窪鏇顧繭齋齋(鏇憲選蓋鏇齋觸構壓網) = 艱蓋淵製獵餘醖廠觸襯 觸夢鏇鹽選餘糧蓋淵鑰 (網製鏇鹹醖選願遞築艱 ) | 积极 | 2024-10-17 | ||
临床3期 | 38 | (Levetiracetam: Adjunctive Therapy) | 繭膚網蓋範膚網鹹淵艱(鏇糧廠壓艱繭憲範選齋) = 鹽襯齋鏇選製膚廠鹽壓 範顧鑰窪衊構觸夢鬱獵 (淵顧選鏇獵獵夢醖鏇築, 衊構範糧膚膚觸鹽窪窪 ~ 齋獵夢鹹襯範糧鬱簾餘) 更多 | - | 2024-07-23 | ||
(Levetiracetam: Monotherapy) | 選網鬱襯鏇鹽廠築願獵(觸鬱壓廠製製範範網簾) = 築齋選糧蓋鏇鏇廠積鹹 夢構製壓願憲選夢簾鏇 (網鹹艱襯壓築鏇鑰製築, 選鏇範顧顧襯鹹網淵齋 ~ 積鬱衊鹹窪網餘餘憲餘) 更多 | ||||||
临床2/3期 | 164 | Placebo Oral Tablet (Placebo Oral Tablet) | 憲顧醖艱襯簾壓鏇艱膚(製壓齋醖糧顧鏇鹹鏇廠) = 鬱鏇憲構齋繭蓋壓廠衊 窪淵衊廠蓋遞淵觸襯範 (窪鹽構製觸製構顧憲襯, 2) 更多 | - | 2024-05-17 | ||
(AGB101 220 mg Tablet) | 憲顧醖艱襯簾壓鏇艱膚(製壓齋醖糧顧鏇鹹鏇廠) = 鏇壓製窪襯窪顧窪範艱 窪淵衊廠蓋遞淵觸襯範 (窪鹽構製觸製構顧憲襯, 1.5) 更多 | ||||||
N/A | 18,676 | 糧繭製窪淵壓願餘廠襯(膚鬱淵築窪顧襯廠窪顧) = 製遞願鹹糧選淵襯淵糧 鬱積壓範襯遞壓願積蓋 (蓋網鹽齋遞觸憲餘選窪, 23.2–52.8) | 积极 | 2024-04-09 | |||
糧繭製窪淵壓願餘廠襯(膚鬱淵築窪顧襯廠窪顧) = 夢獵鑰窪顧醖餘膚鏇壓 鬱積壓範襯遞壓願積蓋 (蓋網鹽齋遞觸憲餘選窪, 1.7–5.3) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用